These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 22901957)

  • 1. fMRI changes in cortical activation during task performance with the unaffected hand partially reverse after ropinirole treatment in de novo Parkinson's disease.
    Tessa C; Diciotti S; Lucetti C; Baldacci F; Cecchi P; Giannelli M; Bonuccelli U; Mascalchi M
    Parkinsonism Relat Disord; 2013 Feb; 19(2):265-8. PubMed ID: 22901957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased and increased cortical activation coexist in de novo Parkinson's disease.
    Tessa C; Lucetti C; Diciotti S; Baldacci F; Paoli L; Cecchi P; Giannelli M; Ginestroni A; Del Dotto P; Ceravolo R; Vignali C; Bonuccelli U; Mascalchi M
    Exp Neurol; 2010 Jul; 224(1):299-306. PubMed ID: 20399207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of ropinirole on visuo-motor test in newly diagnosed Parkinson's disease patients.
    Badarny S; Stern A; Susel Z; Honigman S; Hocherman S
    Acta Neurol Scand; 2006 May; 113(5):294-300. PubMed ID: 16629764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dopamine agonist modifies cortical activity in Parkinson disease: a functional neuroimaging study.
    Lucetti C; Diciotti S; Baldacci F; Tessa C; Ginestroni A; Cecchi P; Paoli L; Del Dotto P; Ceravolo R; Mascalchi M; Bonuccelli U
    Clin Neuropharmacol; 2014; 37(6):166-72. PubMed ID: 25384074
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compensatory cortical mechanisms in Parkinson's disease evidenced with fMRI during the performance of pre-learned sequential movements.
    Mallol R; Barrós-Loscertales A; López M; Belloch V; Parcet MA; Avila C
    Brain Res; 2007 May; 1147():265-71. PubMed ID: 17368575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A functional MRI study of motor dysfunction in Friedreich's ataxia.
    Akhlaghi H; Corben L; Georgiou-Karistianis N; Bradshaw J; Delatycki MB; Storey E; Egan GF
    Brain Res; 2012 Aug; 1471():138-54. PubMed ID: 22771856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson's disease.
    Tompson D; Oliver-Willwong R
    Clin Neuropharmacol; 2009; 32(3):140-8. PubMed ID: 18978485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural and functional evaluation of cortical motor areas in Amyotrophic Lateral Sclerosis.
    Cosottini M; Pesaresi I; Piazza S; Diciotti S; Cecchi P; Fabbri S; Carlesi C; Mascalchi M; Siciliano G
    Exp Neurol; 2012 Mar; 234(1):169-80. PubMed ID: 22226599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic changes in de novo Parkinson's disease after dopaminergic therapy: A proton magnetic resonance spectroscopy study.
    Ciurleo R; Bonanno L; Di Lorenzo G; Bramanti P; Marino S
    Neurosci Lett; 2015 Jul; 599():55-60. PubMed ID: 26007705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Levodopa-sensitive, dynamic changes in effective connectivity during simultaneous movements in Parkinson's disease.
    Palmer SJ; Eigenraam L; Hoque T; McCaig RG; Troiano A; McKeown MJ
    Neuroscience; 2009 Jan; 158(2):693-704. PubMed ID: 18722512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
    Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
    Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease.
    Brooks DJ; Abbott RJ; Lees AJ; Martignoni E; Philcox DV; Rascol O; Roos RA; Sagar HJ
    Clin Neuropharmacol; 1998; 21(2):101-7. PubMed ID: 9579296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH; Ha JH; Cho IS; Lee MC
    J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.
    Korczyn AD; Brooks DJ; Brunt ER; Poewe WH; Rascol O; Stocchi F
    Mov Disord; 1998 Jan; 13(1):46-51. PubMed ID: 9452325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa influences striatal activity but does not affect cortical hyper-activity in Parkinson's disease.
    Martinu K; Degroot C; Madjar C; Strafella AP; Monchi O
    Eur J Neurosci; 2012 Feb; 35(4):572-83. PubMed ID: 22304628
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group.
    Rascol O; Brooks DJ; Brunt ER; Korczyn AD; Poewe WH; Stocchi F
    Mov Disord; 1998 Jan; 13(1):39-45. PubMed ID: 9452324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy].
    Buchwald B; Angersbach D; Jost WH
    Fortschr Neurol Psychiatr; 2007 Apr; 75(4):236-41. PubMed ID: 17427044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Ropinirole in the treatment of Parkinson's disease: an update].
    Vivancos-Matellano F
    Rev Neurol; 2006 May 1-15; 42(9):542-8. PubMed ID: 16676278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
    Hauser RA; Rascol O; Korczyn AD; Jon Stoessl A; Watts RL; Poewe W; De Deyn PP; Lang AE
    Mov Disord; 2007 Dec; 22(16):2409-17. PubMed ID: 17894339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Task specific influences of Parkinson's disease on the striato-thalamo-cortical and cerebello-thalamo-cortical motor circuitries.
    Lewis MM; Slagle CG; Smith AB; Truong Y; Bai P; McKeown MJ; Mailman RB; Belger A; Huang X
    Neuroscience; 2007 Jun; 147(1):224-35. PubMed ID: 17499933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.